Brief: Theranexus Cash Position On 31 December 2018 15.2 Million Euros
Feb 13 (Reuters) - THERANEXUS SA ALTHX.PA :
* CASH POSITION ON 31 DECEMBER 2018 EUR 15.2 MILLION
* RESULTS OF THN102 PARKINSONS DISEASE TRIAL EXPECTED IN H1
2019
* THN102 PHASE II TRIAL ON NARCOLEPSY TRIAL EXPECTED IN NEXT
FEW
WEEKS
* THN201 ALZHEIMER'S DISEASE TRIAL RESULTS EXPECTED BY END
2019
* THN101 NEUROPATHIC PAIN TRIAL DUE TO BEGIN THIS YEAR
Source text: https://bit.ly/2WZGCpz
Further company coverage: ALTHX.PA
(Gdynia Newsroom)
((Gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))
Recent news on Thx Pharma SA
See all newsBrief: Theranexus And BBDF Announce Final And Positive Safety And Efficacy Data In The Phase I/II Trial Testing Batten-1
Brief: Theranexus End-Dec Total Available Funds Stood At EUR 4.9 Mln
Brief: Theranexus Declares Encouraging Prelim Results For Batten Disease Drug
Brief: Theranexus And BBDF Granted Positive Opinion By EMA For Design Of Batten-1 Phase III Trial
Brief: Theranexus And BBDF Win FDA Approval On Endpoints For Phase III Trial To Evaluate Batten-1 In CLN3 Batten Disease